WEST LAFAYETTE, Ind., Feb. 12, 2019 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology companythat is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today that the protocol for the company's Phase 3 clinical trial, OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer, has been amended to
"This camera system will equip surgeons with a more fortified toolkit for detecting cancerous lesions," said Martin Low, CEO of On Target Laboratories. "Our team recognizes the benefits that both cancer patients and medical professionals experience when provided with more flexible surgical equipment options. It is our mission at On Target to improve the health and wellbeing of cancer patients through our unique pipeline of tumor-targeted compounds and the successful completion of this study will further advance this effort."
"Adjusting our technology to support OTL38 and participate in the Phase 3 clinical trial is an important step for our spectrum fluorescence imaging platform," said Richard Meester, CEO of Quest Medical Imaging. "Providing surgeons with visual aids to detect cancerous lesions through our real-time imaging platform will improve patient care and get us one step closer to achieving our mission of fighting cancer with light and improving patient outcomes."
The OTL38 clinical trial is a Phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery. The study is to confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by palpation and visualization under normal light in patients with FR+ ovarian cancer.
About On Target Laboratories, Inc.
On Target Laboratories Inc. discovers, develops and commercializes small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue. These conjugates can be used by doctors, including surgeons, worldwide to better diagnose and treat a wide range of diseases from cancer to inflammation-related disorders. OTL38 is currently under clinical development for use in ovarian and lung cancer surgery. For more information visit www.ontargetlaboratories.com.
About Quest Medical Imaging BV
Quest Medical Imaging designs and manufactures cutting-edge camera systems for medical applications ranging from fluorescent imaging to photo-dynamic therapy.
Quest Medical Imaging has built its main camera system, The Quest SpectrumŪ Platform, to be used both for external and minimal invasive imaging.
Travis Kruse, Ph.D.Russo Partners LLCPhone: 212-845-4272Email: firstname.lastname@example.org
Purdue Research Foundation:
Tom CoynePhone: 765-588-1044Email: email@example.com
Quest Medical Imaging B.V.R.J.C. MeesterPhone : +31 651 410 282Email: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/on-target-laboratories-announces-amendment-to-ongoing-phase-3-trial-expanding-camera-system-compatibility-300793629.html
SOURCE On Target Laboratories, Inc.
Subscribe to our Free Newsletters!